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c o r r e s p o n d e n c e
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Bevacizumab in Neoadjuvant Treatment for Breast Cancer 
To the Editor: The results of two studies, by von 
Minckwitz et al. (GeparQuinto [GBG44] trial; 
ClinicalTrials.gov number, NCT00567554)1 and 
Bear et al. (National Surgical Adjuvant Breast and 
Bowel Project [NSABP] B-40 trial, NCT00408408)2 
(Jan. 26 issue), indicate an additional value of 
bevacizumab in neoadjuvant chemotherapy in pa-
tients with breast cancer. However, previous clin-
ical studies have shown discrepant results for 
bevacizumab in the treatment of metastatic 
breast cancer. As suggested in the editorial in the 
same issue,3 the additional value of bevacizumab 
may be chemotherapy-specific. More important, 
we believe that the timing of bevacizumab ad-
ministration (before or after chemotherapy) may 
have a considerable effect on the delivery of che-
motherapy to tumors,4 leading to differences in 
the efficacy of combination therapy. Data are 
lacking from clinical trials in which patients with 
cancer are randomly assigned to different admin-
istration schedules. Until these data are avail-
able, observational data may be valuable to eluci-
date whether drug scheduling affects the efficacy 
of combination therapy. We wonder in which se-
quence bevacizumab and chemotherapy were ad-
ministered in the study by Bear et al.2 To gain 
more insight into scheduling as a potential con-
tributing factor in efficacy, we think that the se-
quence of as well as the interval between beva-
cizumab and chemotherapy administration should 
be clearly defined for each clinical trial.
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To the Editor: In the article on the NSABP B-40 
trial of neoadjuvant chemotherapy with or with-
out bevacizumab, a clear definition of hormone-
receptor–positive disease was not provided, where-
as in the accompanying article on the GBG44 
trial, hormone-receptor–positive disease was de-
fined with the use of a 10% cutoff on immuno-
histochemical staining. Hence, one cannot rule 
out the possibility that a significant number of 
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cases of hormone-receptor–positive disease in 
the NSABP B-40 trial, which were defined by in-
dividual investigators, could have been classified 
as triple-negative with the use of the criterion of 
the GBG44 trial (<10% of cells positive for either 
estrogen-receptor protein or progesterone-recep-
tor protein), leading to a change in the assess-
ment of the effect of bevacizumab in patients with 
hormone-receptor–positive disease versus patients 
with triple-negative disease. The differences be-
tween the two trials with respect to rates of path-
ological complete response, defined as the ab-
sence of invasive disease in the breast, irrespective 
of nodes, were in favor of bevacizumab (16.5% 
without bevacizumab vs. 20.5% with bevacizu-
mab in the GBG44 trial, and 28.2% vs. 34.5% in 
the NSABP B-40 trial), but neither trial revealed a 
significant difference when complete response 
inclusive of both breast and lymph nodes was as-
sessed.1 Future trial designs should include a 
more precise definition and quantitative assess-
ment of hormone-receptor–positive disease,2 in 
addition to agreement on a standardized defini-
tion of pathological complete response.
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To the Editor: The editorial on the NSABP B-40 
and the GBG44 trials correctly contends that the 
bevacizumab controversy hinges on whether cer-
tain surrogate end points are useful for predict-
ing overall survival and drug efficacy. The au-
thors of the editorial raise two key questions: is 
progression-free survival a surrogate end point 
for metastatic breast cancer, and is pathological 
complete response in the neoadjuvant setting a 
surrogate for overall survival? Data from 17 clin-
ical trials of bevacizumab show that the answer 
to the first question is no.1 In the neoadjuvant 
setting, the data from the NSABP B-40 and 
GBG44 trials are so distant from overall survival 
as to be clinically unconvincing. Rates of patho-
logical complete response in the breast alone are 
hardly appropriate as compared with the more 
clinically meaningful rate of pathological com-
plete response in breast and axillary nodes. Ex-
tensive data1 and recent articles in the Journal2,3 
all indicate that bevacizumab has marginal clini-
cal efficacy. The statement that the decision by 
the Food and Drug Administration (FDA) “to 
withdraw the indication of bevacizumab for meta-
static breast cancer will be further called into 
question” is a distraction. Patient well-being re-
quires better clinical data, not more debate.
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Dr. von Minckwitz and Colleagues Reply: We 
cannot prove van der Veldt and Smit’s hypothesis, 
since we did not capture information on when 
the patients received bevacizumab in relation to 
chemotherapy in the GBG44 trial. According to 
the protocol, the first infusion had to be admin-
istered before chemotherapy; thereafter, the se-
quence was up to the investigator. However, 
because of the long half-life of bevacizumab, we 
would not expect that sequence would make a 
major difference.
A total of 65 of 1948 participants in our study 
(3.3%) had hormone-receptor levels between 1% 
and 9%. The rate of pathological complete re-
sponse in this small cohort was 20.0% without 
bevacizumab and 33.3% with bevacizumab, which 
is somewhat lower than that among patients 
with hormone-receptor levels below 1%, but the 
absolute difference in pathological complete re-
sponse was similar to that in the overall cohort 
of patients with hormone-receptor–negative dis-
ease. A significant positive effect of bevacizu-
mab was seen in triple-negative tumors with the 
use of either definition of hormone-receptor 
negativity (<10% or <1% of cells positive for either 
estrogen-receptor protein or progesterone-recep-
tor protein).
The New England Journal of Medicine 
Downloaded from nejm.org at VRIJE UNIVERSITEIT on October 29, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
correspondence
n engl j med 366;17 nejm.org april 26, 2012 1639
Our group just analyzed data from 6377 pa-
tients treated in neoadjuvant trials in Germany 
and recommended the most conservative defini-
tion of a pathological complete response (ypT0, 
ypN0) (i.e., no invasive and no noninvasive re-
sidual disease in breast and nodes) to provide 
the best discrimination between a favorable and 
an unfavorable long-term outcome. Of note, this 
conservative definition was used as a primary 
end point in our study (as requested by Gabor 
Miklos) and showed a significant difference in 
pathological complete response.
Studies have repeatedly shown that the path-
ological complete response correlates best with 
survival among patients with triple-negative dis-
ease.1,2 This is the subgroup in which we saw 
the largest effect of bevacizumab. However, we do 
not recommend extrapolation of data on early 
neoadjuvant treatment or from treatment of pa-
tients with metastatic cancer to the long-term 
effect of bevacizumab in early breast cancer. We 
have to await data on overall survival from our 
study and the NSABP B-40 study, as well as from 
adjuvant trials (especially those focused on triple-
negative breast cancer) to make a final assessment.
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Dr. Bear and Colleagues Reply: In response to 
van der Veldt and Smit’s provocative question: we 
regret that space did not allow us to provide full 
details about treatment. However, a link to the 
complete protocol was included and is also avail-
able at www.cancer.gov/clinicaltrials/search/view? 
cdrid=515432&version=healthprofessional. Beva-
cizumab was administered on day 1 of each of the 
first six cycles of chemotherapy and, according to 
the protocol, was initially administered before 
the chemotherapy drugs (in approximately 250 pa-
tients who were randomly assigned to treatment); 
however, after the second protocol amendment 
in March 2008, each institution was allowed to 
follow its own policies regarding the sequence of 
administration. Whether the timing between the 
administration of bevacizumab and the infusion 
of chemotherapy on the same day would affect the 
delivery of chemotherapy drugs to the tumor, as 
suggested by van der Veldt and Smit, is uncertain.
Somlo raises an important caveat regarding 
definitions of hormone-receptor–positive breast 
cancer. Current pathological guidelines now de-
fine the presence of more than 1% of cells that 
are positive for either estrogen-receptor protein 
or progesterone-receptor protein on immunohisto-
chemical staining as “positive,”1 but it could be 
argued that “weakly positive” tumors with less 
than 10% of cells that are positive may not be 
truly hormone-sensitive. As stated, if a significant 
proportion of the tumors classified as hormone-
receptor–positive were in the 1 to 10% range, 
our results may have been more similar to those 
in the GBG44 trial. However, assays from cores 
may not be accurate; in a study by Tamaki et al., 
concordance rates between cores and surgical 
specimens were 92.9% for estrogen-receptor 
positivity and 77.9% for progesterone-receptor 
positivity.2 Eventually, molecular analysis of the 
tissues we obtained before treatment may clarify 
this issue.
We agree with Gabor Miklos that overall sur-
vival is the key end point for including new 
agents in the treatment of early-stage breast 
cancer, and we await sufficient events to report 
on this end point. Pathological complete response 
in the breast was by design the primary end 
point for the NSABP B-40 trial. Although it is true 
that the pathologic status of breast plus nodes is 
a “stronger” predictor of patient outcomes after 
neoadjuvant therapy, it is questionable whether 
nodal status really should be considered a “re-
sponse” unless the presence of cancer in the 
nodes has been proved before therapy.
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The Editorialists Reply: In response to Gabor 
Miklos: we agree that “better clinical data” are 
needed. Looking at the phase 3 data, we can con-
clude that there is a variable prolongation of pro-
gression-free survival, which has not translated 
into a significant improvement in overall surviv-
al.1 However, from these data one cannot con-
clude that progression-free survival is an invalid 
clinical end point. We do not think that the deci-
sion by the FDA to withdraw the indication for 
bevacizumab in women with breast cancer is a 
“distraction,” but goes to the heart of the matter 
of surrogate end points.1 The overall benefit of 
bevacizumab in metastatic breast cancer appears 
to be modest. On the basis of data from E2100 
(NCT00028990), we have recently found that the 
use of bevacizumab in metastatic breast cancer is 
not cost-effective and does not represent a good 
value for health care dollars.2 We are hopeful 
that these controversies will indeed kindle a fire 
in the research community so that clinical trials 
are conducted in a smarter and more efficient 
manner. We also sincerely hope that effective 
predictive markers, perhaps as suggested by data 
from A Randomized Phase III Trial to Evaluate 
Bevacizumab in Combination with Trastuzumab 
Plus Docetaxel as First-Line Therapy for HERZ-
Positive Locally Recurrent/Metastatic Breast Can-
cer (AVEREL, NCT00391092),3 will advance the 
use of antiangiogenic agents.
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Antenatal Thyroid Screening and Childhood Cognitive Function
To the Editor: Lazarus and colleagues (Feb. 9 
issue)1 administered levothyroxine to pregnant 
women who had a serum thyrotropin level above 
the 97.5th percentile, a serum free thyroxine level 
below the 2.5th percentile, or both to investigate 
the potential benefit on later cognitive function 
in their children. However, it is questionable 
whether these cutoff values were appropriate, 
given the known iodine deficiency among young 
women in the United Kingdom2 and indeed in a 
subgroup of women in the trial.3 If reference 
ranges derived from iodine-sufficient popula-
tions4,5 had been used, the cutoffs would have 
been lower for thyrotropin and higher for free 
thyroxine, thereby increasing the number of 
women who would have been treated (along with 
their respective controls). (Incidentally, the units 
of free thyroxine have been inaccurately convert-
ed on page 494 of the article.) Since thyroid dys-
function may have been underdiagnosed, the sta-
tistical power to detect a significant difference 
may have been reduced. Although the authors 
claim that the study was adequately powered, the 
calculation may have been invalid, since it was 
based on a study that was conducted in an iodine-
sufficient country (the United States), and the 
women in that study had more severe thyroid 
dysfunction (a higher serum thyrotropin level).6 
We consider that these points are pertinent to the 
interpretation of the results of this trial.
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